Krishan Jethwa, GI Radiation Oncologist at Mayo Clinic, shared a post on X:
“Prognostic significance of detectable ctDNA in the NEO-trial
NEO evaluated 3m FOLFOX local excision for T1-3bN0 rectal cancer
Study suggests detectable ctDNA (guardant reveal) was associated with poorer response and persistent cancer.”
